☰

Kent L. Kunze - Publications

Affiliations: 
Medicinal Chemistry University of Washington, Seattle, Seattle, WA 
Area:
Pharmaceutical Chemistry
Website:
https://sop.washington.edu/people/kent-kunze/
Tree Info Similar researchers PubMed Report error

55 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2014 Rock BM, Hengel SM, Rock DA, Wienkers LC, Kunze KL. Characterization of ritonavir-mediated inactivation of cytochrome P450 3A4. Molecular Pharmacology. 86: 665-74. PMID 25274602 DOI: 10.1124/Mol.114.094862  0.473
2014 Sager JE, Lutz JD, Foti RS, Davis C, Kunze KL, Isoherranen N. Fluoxetine- and norfluoxetine-mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19, and CYP3A4. Clinical Pharmacology and Therapeutics. 95: 653-62. PMID 24569517 DOI: 10.1038/Clpt.2014.50  0.423
2013 Zhang N, Seguin RP, Kunze KL, Zhang YY, Jeong H. Characterization of inhibition kinetics of (S)-warfarin hydroxylation by noscapine: implications in warfarin therapy. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 41: 2114-23. PMID 24046330 DOI: 10.1124/Dmd.113.053330  0.462
2013 Lutz JD, VandenBrink BM, Babu KN, Nelson WL, Kunze KL, Isoherranen N. Stereoselective inhibition of CYP2C19 and CYP3A4 by fluoxetine and its metabolite: implications for risk assessment of multiple time-dependent inhibitor systems. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 41: 2056-65. PMID 23785064 DOI: 10.1124/Dmd.113.052639  0.735
2012 Fujioka Y, Kunze KL, Isoherranen N. Risk assessment of mechanism-based inactivation in drug-drug interactions. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 40: 1653-7. PMID 22685217 DOI: 10.1124/Dmd.112.046649  0.337
2012 Peng CC, Shi W, Lutz JD, Kunze KL, Liu JO, Nelson WL, Isoherranen N. Stereospecific metabolism of itraconazole by CYP3A4: dioxolane ring scission of azole antifungals. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 40: 426-35. PMID 22106171 DOI: 10.1124/Dmd.111.042739  0.438
2011 Woods CM, Fernandez C, Kunze KL, Atkins WM. Allosteric activation of cytochrome P450 3A4 by α-naphthoflavone: branch point regulation revealed by isotope dilution analysis. Biochemistry. 50: 10041-51. PMID 22004098 DOI: 10.1021/Bi2013454  0.383
2011 Babu KN, Kunze KL, Nelson WL. Metabolism of diltiazem: A short efficient synthesis of N, N -didesmethyldiltiazem - An important product of N-demethylation Synthesis. 553-554. DOI: 10.1055/S-0030-1258410  0.436
2010 Templeton I, Peng CC, Thummel KE, Davis C, Kunze KL, Isoherranen N. Accurate prediction of dose-dependent CYP3A4 inhibition by itraconazole and its metabolites from in vitro inhibition data. Clinical Pharmacology and Therapeutics. 88: 499-505. PMID 20739919 DOI: 10.1038/Clpt.2010.119  0.402
2010 Hanson KL, VandenBrink BM, Babu KN, Allen KE, Nelson WL, Kunze KL. Sequential metabolism of secondary alkyl amines to metabolic-intermediate complexes: opposing roles for the secondary hydroxylamine and primary amine metabolites of desipramine, (s)-fluoxetine, and N-desmethyldiltiazem. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 38: 963-72. PMID 20200233 DOI: 10.1124/Dmd.110.032391  0.607
2008 Templeton IE, Thummel KE, Kharasch ED, Kunze KL, Hoffer C, Nelson WL, Isoherranen N. Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo. Clinical Pharmacology and Therapeutics. 83: 77-85. PMID 17495874 DOI: 10.1038/Sj.Clpt.6100230  0.458
2007 Zhao P, Lee CA, Kunze KL. Sequential metabolism is responsible for diltiazem-induced time-dependent loss of CYP3A. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 35: 704-12. PMID 17293381 DOI: 10.1124/Dmd.106.013847  0.451
2006 Pearson JT, Hill JJ, Swank J, Isoherranen N, Kunze KL, Atkins WM. Surface plasmon resonance analysis of antifungal azoles binding to CYP3A4 with kinetic resolution of multiple binding orientations. Biochemistry. 45: 6341-53. PMID 16700545 DOI: 10.1021/Bi0600042  0.347
2006 Kunze KL, Nelson WL, Kharasch ED, Thummel KE, Isoherranen N. Stereochemical aspects of itraconazole metabolism in vitro and in vivo. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 34: 583-90. PMID 16415110 DOI: 10.1124/Dmd.105.008508  0.405
2005 Cameron MD, Wen B, Allen KE, Roberts AG, Schuman JT, Campbell AP, Kunze KL, Nelson SD. Cooperative binding of midazolam with testosterone and alpha-naphthoflavone within the CYP3A4 active site: a NMR T1 paramagnetic relaxation study. Biochemistry. 44: 14143-51. PMID 16245930 DOI: 10.1021/Bi051689T  0.698
2005 Regal KA, Kunze KL, Peter RM, Nelson SD. Oxidation of caffeine by CYP1A2: isotope effects and metabolic switching. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 33: 1837-44. PMID 16135658 DOI: 10.1124/Dmd.105.006031  0.475
2005 Zhao P, Kunze KL, Lee CA. Evaluation of time-dependent inactivation of CYP3A in cryopreserved human hepatocytes. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 33: 853-61. PMID 15743977 DOI: 10.1124/Dmd.104.002832  0.352
2004 McConn DJ, Lin YS, Allen K, Kunze KL, Thummel KE. Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 32: 1083-91. PMID 15377640 DOI: 10.1124/Dmd.32.10.1083  0.747
2004 Isoherranen N, Kunze KL, Allen KE, Nelson WL, Thummel KE. Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 32: 1121-31. PMID 15242978 DOI: 10.1124/Dmd.104.000315  0.729
2003 Neal JM, Kunze KL, Levy RH, O'Reilly RA, Trager WF. Kiiv, an in vivo parameter for predicting the magnitude of a drug interaction arising from competitive enzyme inhibition. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 31: 1043-8. PMID 12867493 DOI: 10.1124/Dmd.31.8.1043  0.349
2003 Yao C, Kunze KL, Trager WF, Kharasch ED, Levy RH. Comparison of in vitro and in vivo inhibition potencies of fluvoxamine toward CYP2C19. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 31: 565-71. PMID 12695344 DOI: 10.1124/Dmd.31.5.565  0.345
2003 Zheng YM, Baer BR, Kneller MB, Henne KR, Kunze KL, Rettie AE. Covalent heme binding to CYP4B1 via Glu310 and a carbocation porphyrin intermediate. Biochemistry. 42: 4601-6. PMID 12693958 DOI: 10.1021/Bi020667T  0.32
2001 Yao C, Kunze KL, Kharasch ED, Wang Y, Trager WF, Ragueneau I, Levy RH. Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2. Clinical Pharmacology and Therapeutics. 70: 415-24. PMID 11719727 DOI: 10.1067/Mcp.2001.119724  0.323
2001 Henne KR, Kunze KL, Zheng YM, Christmas P, Soberman RJ, Rettie AE. Covalent linkage of prosthetic heme to CYP4 family P450 enzymes. Biochemistry. 40: 12925-31. PMID 11669629 DOI: 10.1021/Bi011171Z  0.335
2000 Gibbs MA, Baillie MT, Shen DD, Kunze KL, Thummel KE. Persistent inhibition of CYP3A4 by ketoconazole in modified Caco-2 cells. Pharmaceutical Research. 17: 299-305. PMID 10801218 DOI: 10.1023/A:1007550717526  0.389
1998 Regal KA, Howald WN, Peter RM, Gartner CA, Kunze KL, Nelson SD. Subnanomolar quantification of caffeine's in vitro metabolites by stable isotope dilution gas chromatography-mass spectrometry. Journal of Chromatography. B, Biomedical Sciences and Applications. 708: 75-85. PMID 9653949 DOI: 10.1016/S0378-4347(97)00656-7  0.347
1998 Racha JK, Rettie AE, Kunze KL. Mechanism-based inactivation of human cytochrome P450 1A2 by furafylline: detection of a 1:1 adduct to protein and evidence for the formation of a novel imidazomethide intermediate. Biochemistry. 37: 7407-19. PMID 9585555 DOI: 10.1021/Bi973011M  0.468
1998 Racha JK, Kunze KL. Stereochemical Evidence for Decomposition of Reactive Intermediates by Active Site Water in the Metabolism of 8-Alkyl Xanthines by P450 1A2 Journal of the American Chemical Society. 120: 5337-5338. DOI: 10.1021/Ja980337P  0.348
1997 Tran A, Rey E, Pons G, Rousseau M, d'Athis P, Olive G, Mather GG, Bishop FE, Wurden CJ, Labroo R, Trager WF, Kunze KL, Thummel KE, Vincent JC, Gillardin JM, et al. Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants. Clinical Pharmacology and Therapeutics. 62: 490-504. PMID 9390105 DOI: 10.1016/S0009-9236(97)90044-8  0.41
1997 Kharasch ED, Russell M, Mautz D, Thummel KE, Kunze KL, Bowdle A, Cox K. The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions. Anesthesiology. 87: 36-50. PMID 9232132 DOI: 10.1097/00000542-199707000-00006  0.395
1997 Gallagher EP, Kunze KL, Stapleton PL, Eaton DL. The kinetics of aflatoxin B1 oxidation by human cDNA-expressed and human liver microsomal cytochromes P450 1A2 and 3A4. Toxicology and Applied Pharmacology. 141: 595-606. PMID 8975785 DOI: 10.1006/Taap.1996.0326  0.424
1997 Thummel KE, Kunze KL, Shen DD. Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction Advanced Drug Delivery Reviews. 27: 99-127. DOI: 10.1016/S0169-409X(97)00039-2  0.38
1996 McHugh TE, Atkins WM, Rachal JK, Kunze KL, Eaton DL. Binding of the aflatoxin-glutathione conjugate to mouse glutathione S- transferase A3-3 is saturated at only one ligand per dimer Journal of Biological Chemistry. 271: 27470-27474. PMID 8910329 DOI: 10.1074/Jbc.271.44.27470  0.35
1996 Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP, Barr DM, Gillies BS, Thummel KE. First-pass metabolism of midazolam by the human intestine Clinical Pharmacology and Therapeutics. 60: 14-24. PMID 8689807 DOI: 10.1016/S0009-9236(96)90162-9  0.347
1996 Eaton DL, Gallagher EP, Bammler TK, Kunze KL. Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity. Pharmacogenetics. 5: 259-74. PMID 8563766 DOI: 10.1097/00008571-199510000-00001  0.33
1994 Kunze KL, Trager WF. Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline. Chemical Research in Toxicology. 6: 649-56. PMID 8292742 DOI: 10.1021/Tx00035A009  0.397
1993 Thummel KE, Lee CA, Kunze KL, Nelson SD, Slattery JT. Oxidation of acetaminophen to N-acetyl-p-aminobenzoquinone imine by human CYP3A4. Biochemical Pharmacology. 45: 1563-9. PMID 8387297 DOI: 10.1016/0006-2952(93)90295-8  0.449
1992 O'Reilly RA, Goulart DA, Kunze KL, Neal J, Gibaldi M, Eddy AC, Trager WF. Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects. Clinical Pharmacology and Therapeutics. 51: 656-67. PMID 1611805 DOI: 10.1038/clpt.1992.78  0.307
1992 Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Craig Eddy A, Aoyama T, Gelboin HV, Gonzalez FJ, Trager WF. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: A role for P-4502C9 in the etiology of (S)-warfarin - Drug interactions Chemical Research in Toxicology. 5: 54-59. PMID 1581537 DOI: 10.1021/Tx00025A009  0.406
1992 Heimark LD, Wienkers L, Kunze K, Gibaldi M, Eddy AC, Trager WF, O'Reilly RA, Goulart DA. The mechanism of the interaction between amiodarone and warfarin in humans. Clinical Pharmacology and Therapeutics. 51: 398-407. PMID 1563209 DOI: 10.1038/Clpt.1992.39  0.391
1991 Kunze KL, Eddy AC, Gibaldi M, Trager WF. Metabolic enantiomeric interactions: the inhibition of human (S)-warfarin-7-hydroxylase by (R)-warfarin. Chirality. 3: 24-9. PMID 2039681 DOI: 10.1002/Chir.530030106  0.404
1982 Ortiz de Montellano PR, Kunze KL, Cole SP, Marks GS. Differential inhibition of hepatic ferrochelatase by the isomers of N-ethylprotoporphyrin IX. Biochemical and Biophysical Research Communications. 103: 581-6. PMID 7332558 DOI: 10.1016/0006-291X(81)90491-5  0.538
1982 Ortiz de Montellano PR, Kunze KL. Cytochrome P-450 inactivation: structure of the prosthetic heme adduct with propyne. Biochemistry. 20: 7266-71. PMID 7317380 DOI: 10.1021/Bi00528A033  0.584
1982 Ortiz de Montellano PR, Mico BA, Mathews JM, Kunze KL, Miwa GT, Lu AY. Selective inactivation of cytochrome P-450 isozymes by suicide substrates. Archives of Biochemistry and Biophysics. 210: 717-28. PMID 7305355 DOI: 10.1016/0003-9861(81)90239-3  0.473
1982 Ortiz de Montellano PR, Kunze KL, Beilan HS, Wheeler C. Destruction of cytochrome P-450 by vinyl fluoride, fluroxene, and acetylene. Evidence for a radical intermediate in olefin oxidation. Biochemistry. 21: 1331-9. PMID 6122467 DOI: 10.1021/Bi00535A035  0.574
1982 Ortiz de Montellano PR, Kunze KL, Augusto O. Hemoprotein destruction. Iron-nitrogen shift of a phenyl group in a porphyrin complex Journal of the American Chemical Society. 104: 3545-3546. DOI: 10.1021/Ja00376A069  0.523
1981 Ortiz de Montellano PR, Kunze KL. Shift of the acetylenic hydrogen during chemical and enzymatic oxidation of the biphenylacetylene triple bond. Archives of Biochemistry and Biophysics. 209: 710-2. PMID 7294821 DOI: 10.1016/0003-9861(81)90333-7  0.411
1981 Ortiz de Montellano PR, Beilan HS, Kunze KL. N-Methylprotoporphyrin IX: chemical synthesis and identification as the green pigment produced by 3,5-diethoxycarbonyl-1,4-dihydrocollidine treatment. Proceedings of the National Academy of Sciences of the United States of America. 78: 1490-4. PMID 6940170 DOI: 10.1073/pnas.78.3.1490  0.536
1981 Ortiz de Montellano PR, Kunze KL, Cole SP, Marks GS. Inhibition of hepatic ferrochelatase by the four isomers of N-methylprotoporphyrin IX. Biochemical and Biophysical Research Communications. 97: 1436-42. PMID 6894236 DOI: 10.1016/S0006-291X(80)80026-X  0.545
1981 Ortiz de Montellano PR, Kunze KL. Formation of N-phenylheme in the hemolytic reaction of phenylhydrazine with hemoglobin Journal of the American Chemical Society. 103: 6534-6536. DOI: 10.1021/Ja00411A061  0.365
1981 Kunze KL, Ortiz de Montellano PR. N-Methylprotoporphyrin IX. Identification by NMR of the nitrogen alkylated in each of the four isomers Journal of the American Chemical Society. 103: 4225-4230. DOI: 10.1021/Ja00404A042  0.388
1980 Ortiz de Montellano PR, Kunze KL. Inactivation of hepatic cytochrome P-450 by allenic substrates. Biochemical and Biophysical Research Communications. 94: 443-9. PMID 7396909 DOI: 10.1016/0006-291X(80)91251-6  0.495
1980 Farrell GC, Correia MA, Schmid R, Montellano PROd, Kunze KL. Exogenous Heme Functionally Reconstitutes Hepatic Cytochrome P-450 In Vivo Microsomes, Drug Oxidations and Chemical Carcinogenesis. 587-590. DOI: 10.1016/B978-0-12-187701-9.50115-7  0.343
1979 Farrell GC, Schmid R, Kunze KL, Ortiz de Montellano PR. Exogenous heme restores in vivo functional capacity of hepatic cytochrome P-450 destroyed by allylisopropylacetamide. Biochemical and Biophysical Research Communications. 89: 456-63. PMID 486175 DOI: 10.1016/0006-291X(79)90651-X  0.477
1979 Ortiz De Montellano PR, Kunze KL, Yost GS, Mico BA. Self-catalyzed destruction of cytochrome P-450: Covalent binding of ethynyl sterols to prosthetic heme Proceedings of the National Academy of Sciences of the United States of America. 76: 746-749. PMID 284396 DOI: 10.1073/pnas.76.2.746  0.646
Show low-probability matches.